# Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation

> **NCT04018937** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Emory University** · enrollment: 43 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Alemtuzumab
- **DRUG:** Fludarabine
- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT04018937
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-22
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04018937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04018937, "Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04018937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*